1. Home
  2. ACU vs CHRS Comparison

ACU vs CHRS Comparison

Compare ACU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acme United Corporation.

ACU

Acme United Corporation.

SELL

Current Price

$62.07

Market Cap

214.7M

ML Signal

SELL

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

SELL

Current Price

$1.04

Market Cap

177.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ACU
CHRS
Founded
1867
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
214.7M
177.7M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
ACU
CHRS
Price
$62.07
$1.04
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
46.0K
★ 1.6M
Earning Date
10-23-2026
11-05-2026
Dividend Yield
★ 1.03%
N/A
EPS Growth
1.63
★ 472.00
EPS
★ 1.46
N/A
Revenue
★ $196,541,816.00
N/A
Revenue This Year
$14.99
$44.19
Revenue Next Year
$3.98
$65.06
P/E Ratio
$42.60
★ N/A
Revenue Growth
★ 1.05
N/A
52 Week Low
$35.50
$0.97
52 Week High
$64.87
$2.62

Technical Indicators

Market Signals
Indicator
ACU
CHRS
Relative Strength Index (RSI) 49.93 35.54
Support Level $59.74 N/A
Resistance Level $64.03 $1.53
Average True Range (ATR) 1.37 0.07
MACD -0.29 -0.01
Stochastic Oscillator 22.44 18.15

Price Performance

Historical Comparison
ACU
CHRS

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: